bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract A075: Using social marketing principles to address lung cancer screening among Chinese Americans
Authors: Kwon Simona , Tan Yi-Ling , Chong Stella , Luu Binh , Tsai William , Ah-Yune Judy , Love Jamie , Vang Suzanne 
Published: December 2023

Abstract
Background: Lung cancer is the second and fourth most common cancer diagnosed among Chinese American men and women respectively. Screening can detect lung cancer in its early, most treatable stages. In 2022, the US Preventive Services Task Force (USPSTF) expanded their annual lung cancer eligibility criteria. Despite the disproportionately high rates of lung cancer among Chinese Americans, prior research suggest that screening rates in Chinese Americans remain low due to complex and systemic barriers. Objective: We seek to describe the development of a culturally and linguistically relevant project to provide education and outreach on lung cancer screening for Chinese Americans. Methods: The project was guided by the principles of participatory cultural adaptation and social marketing to develop sustainable education and outreach efforts and identify appropriate messaging and channels. This included a scoping review focusing on barriers to lung cancer screening in Chinese Americans and a survey of Chinese-serving physicians. A transdisciplinary advisory group guided the development and implementation of the project and design of the multi-media materials. We leveraged existing regional and national networks to maximize the outreach to Chinese American communities across the US. Results: Using social marketing principles, we developed culturally tailored multi-media materials to raise awareness of the eligibility criteria for lung cancer screening and address barriers toward screening in Chinese Americans. This included the following: 1) a bilingual website with information and resources for Chinese Americans, including an eligibility quiz; 2) digital stories featuring patient stories which directly address perceived barriers toward lung screening; and 3) materials for physicians. We will share the cultural adaptation process and present data on the reach of the social media outreach. Conclusion: There is a need to develop culturally and linguistically relevant education and outreach efforts to actively promote lung cancer screening and address barriers to screening among high-risk Chinese Americans, in order to reduce lung cancer disparities.
Citation Format: Simona Kwon, Yi-Ling Tan, Stella Chong, Binh Luu, William Tsai, Judy Ah-Yune, Jamie Love, Suzanne Vang. Using social marketing principles to address lung cancer screening among Chinese Americans [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr A075.
Abstract A083: Initiation and persistence of hormone therapy in endocrine positive breast cancer at an urban safety-net hospital
Authors: Solfisburg Quinn S. , Beaulieu-Jones Brendin R. , Cassidy Michael R. , Ko Naomi Y. 
Published: December 2023

Abstract
Background: Evidence demonstrates inequities in receipt and persistence of hormone therapy among breast cancer patient populations based on race, ethnicity, insurance, and language. Institutions where patients seek cancer care may have an impact on receipt of treatment. It is unknown whether safety net hospitals, servicing a vulnerable patient population, exhibit inequities in receipt of hormone therapy for breast cancer. Study Design: We performed a retrospective study of patients diagnosed with all stages of hormone positive (ER+ and/or PR +) breast cancer treated at a safety net institution over the five year period from January 1, 2009 to December 31, 2013. The initiation of and persistence of hormone therapy were assessed by race, ethnicity, insurance status, and primary language. Persistence of therapy was defined as defined as at least 3 prescriptions (90 day supply) or more than 1 visit after start of treatment documenting taking treatment. Results: A total of 599 women were identified. The median age was 59 years, 58% were non-White, 32% were non-English-speaking, and 35% had Medicaid or no insurance. A total of 506 (84%) were started on hormone therapy. In multivariate regression analysis, the rate of endocrine therapy initiation was associated with higher stage at diagnosis, post-menopausal status, and HER2 negative status. Non-white race, Hispanic/Latino ethnicity, non-English-language, and Medicaid/no insurance were not significantly associated with or without initiation of hormone therapy. 93% of patients started on hormone therapy had evidence of continued treatment, 91% had evidence of continued treatment at 1 year, 75% finished their recommended course of hormone therapy. Conclusion: At an urban safety-net hospital, we do not observe inequities in the initiation of endocrine therapy for breast cancer by race, ethnicity, insurance, or language. Persistence of therapy was similar to nationally reported data. Additional research by hospital type, and granular reasons for non-adherence are warranted.
Citation Format: Quinn S. Solfisburg, Brendin R. Beaulieu-Jones, Michael R. Cassidy, Naomi Y. Ko. Initiation and persistence of hormone therapy in endocrine positive breast cancer at an urban safety-net hospital [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr A083.
Abstract A105: Healthy behaviors among non-Hispanic Black and Hispanic people affected by cancer during the post-treatment survivorship
Authors: Seven Memnun , Moraitis Ann Marie , Hammer Marilyn J. , Pearlman Jessica , Reid Allecia , Sturgeon Susan , Wenzel Jennifer 
Published: December 2023

Abstract
Background: Racial and ethnic minoritized people, historically experience inequities, are disproportionately affected by suboptimal body weight, diet, and sedentary lifestyle. However, limited studies focus on cancer survivors' experiences developing and maintaining healthy behaviors, particularly in Non-Hispanic Black (NHB) and Hispanic people. Objective. This study aimed to understand the experiences of NHB and Hispanic people affected by cancer in developing and maintaining positive health behaviors beyond a cancer diagnosis. Methods. The data was collected in a mixed-method study through semi-structured interviews with 29 NHB and Hispanic cancer survivors between June- October 2022. Conventional content analysis was used. Results. The lived experiences of cancer survivors were narrated in three themes; 1- Impact of a cancer diagnosis on oneself, 2- Facilitators and Barriers to health and health behaviors, and 3- Utilization of available sources for health. Facilitators and barriers to health and health behaviors were further explored as biological (e.g., symptoms, comorbidities), behavioral (e.g., help-seeking behavior, sleep pattern), physical/built environment (e.g., available sources, neighborhood), and sociocultural environment (e.g., income, transportation, knowledge, culture, upbringing, household and community composition, social and family network), and healthcare system-related factors (e.g., insurance coverage, personal preferences, perceived discrimination, and stigma). Conclusion. NHB and Hispanic people affected by cancer, specifically those living in disadvantaged neighborhoods with limited sources or where they feel discriminated and stereotyped, those with limited income and transportation, and those with physical, social, or mental health problems, appeared to have challenges prioritizing health behaviors and maintaining healthy living. Implications for Practice. Biological, behavioral, and psychosocial determinants of health behaviors should be addressed through multilevel collaborations among different levels of partners. Keywords. Cancer survivorship, health behaviors, racial disparities, non-Hispanic Black and Hispanic people
Citation Format: Memnun Seven, Ann Marie Moraitis, Marilyn J. Hammer, Jessica Pearlman, Allecia Reid, Susan Sturgeon, Jennifer Wenzel. Healthy behaviors among non-Hispanic Black and Hispanic people affected by cancer during the post-treatment survivorship [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr A105.
Abstract A132: Time to treatment by neighborhood among endometrial intraepithelial neoplasia and endometrial cancer patients
Authors: Wang Victoria , Reid Hadley , Pelletier Andrea , Russell Trinity , Chen Lucy , Marsh Reagan , Feltmate Colleen , Wright Alexi , Elias Kevin 
Published: December 2023

Abstract
Objective: To examine interval wait time for surgery in EIN and Endometrial Cancer patients at a single institution and identify potential disparities in access to care Methods: At this single institution, five priority neighborhoods where medically underserved populations reside have been designated from a Community Health Needs Assessment. We performed a retrospective chart review of patients with EIN or endometrial cancer at a single institution between 2016-2019. Patients from one of five priority neighborhoods were compared with patients from other zip codes within the same state. Results: 100 patients from priority neighborhoods and 104 patients from other neighborhoods within the same state were identified. Mean age was similar (59.74 vs 58.15 yrs, p 0.372) and rates of private insurance status were similar (66% vs 52%, p 0.08). Priority neighborhood patients were more likely to identify as Black or Hispanic (30.0% vs 4.81%; 18.0% vs 0%, p &lt;0.001), and were more likely to speak a non-English primary language (19.0% vs 2.88%, p 0.005). Priority neighborhood patients had a higher Charlson Deyo co-morbidity score (2.44 vs 2.49, p 0.809). Patients had a similar rates of advanced stage disease (Stage III or IV 16 vs 16, p 0.213) and histologic subtype (Endometrioid 47.5% vs 59.6%; Serous or Clear Cell 13.46% vs 14.75%, p 0.962). The mean interval to treatment by primary surgery from referral visit was 68.9 days for non-priority neighborhood patients compared to 80.12 days for priority neighborhood patients (p 0.478). In univariate analysis, race/ethnicity, primary language, and insurance status were not significant factors impacting time to treatment. Conclusion: Interval wait time to primary surgery among a single institution cohort was longer for priority neighborhood patients. This study highlights potential barriers to healthcare access that are unaddressed by current systems.
Citation Format: Victoria Wang, Hadley Reid, Andrea Pelletier, Trinity Russell, Lucy Chen, Reagan Marsh, Colleen Feltmate, Alexi Wright, Kevin Elias. Time to treatment by neighborhood among endometrial intraepithelial neoplasia and endometrial cancer patients [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr A132.
Abstract B004: Dealing with prostate cancer racial disparity: Galeterone and next-generation galeterone analog VNPP433-3β potently inhibits proliferation of prostate cancer cells from African American patient by degrading AR and Mnk1/2
Authors: Thomas Elizabeth , Thankan Retheesh Sulochana , Purushottachar Puranik , Njar Vincent C.O. 
Published: December 2023

Abstract
Prostate cancer incidence and mortality rates are remarkably higher in African-American (AA) men as compared to their European-American (EA) counterparts even after factoring in socio economic status. The disproportionate incidence of prostate cancer and associated mortality in African men is currently becoming more evident as Several studies have reported significant variations in genetic, molecular, epigenetic, microRNA, and cell signaling pathways in patients of Caucasian and African race. As androgen is implicated in prostate cancer progression and about 90% of the cases are Androgen-dependent, blocking androgen action is an effective strategy in treating prostate cancer. Previously, we reported that galeterone and VNPP433-3β, a next generation galeterone analog potently inhibit metastatic castration resistant prostate cancer of Caucasian origin in vitro and in vivo by degrading AR/AR-V7 and Mnk1/2. Since the prostate cancer patients of African descent express significant levels of AR and Mnk1/2, we investigated the efficacy of galeterone and VNPP433-3β in treating prostate cancer of African men. Cell proliferation assay using the cell lines MDA-PCa 2b and RC77 T/E derived from AA prostate cancer patient demonstrates that galeterone and VNPP433-3β can effectively inhibit prostate cancer of African descent at very low concentration. These cell lines are Androgen-sensitive and further biochemical studies reveal that galeterone and VNPP433-3β degrade AR and Mnk1/2 in RC77 T/E and MDA-PCa 2b cell lines, thereby inhibiting its proliferation. Galeterone and VNPP433-3β significantly decrease the half-life of AR in these cell lines by increasing the rate of ubiquitination and proteasomal degradation of AR. Therefore, galeterone and VNPP433-3β hold significant promise for the clinical management of prostate cancer in patients of African descent
Citation Format: Elizabeth Thomas, Retheesh Sulochana Thankan, Puranik Purushottachar, Vincent C.O. Njar. Dealing with prostate cancer racial disparity: Galeterone and next-generation galeterone analog VNPP433-3β potently inhibits proliferation of prostate cancer cells from African American patient by degrading AR and Mnk1/2 [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B004.
Abstract B005: In-silico identification of oxa/thiazole carboxamides as potential breast cancer therapeutic agents with vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitory effect
Authors: Ewell Steven M. , Mequanint Getinet , Sikazwe Donald , Redda Kinfe , Mochona Bereket 
Published: December 2023

Abstract
Vascular Endothelial Growth Factor Receptor (VEGFR-2) is a tyrosine kinase receptor mainly known to be expressed in vascular endothelial cells. Overexpression of VEGFER-2 has been linked to tumor angiogenesis, necessitating the need for VEGFER-2 inhibitors. In-silico screening of oxa/thiazole carboxamide scaffold-bearing compounds retrieved from the ZINC database was conducted to identify potential anticancer agents with VEGFR-2 inhibitory effect. The interaction of VEGFR2 with tivozanib was used to generate a six-point pharmacophore model for screening ZINC chemical database. The virtual screening for potential VEGFR2 inhibitors generated 48 hits. The hits were filtered and ranked using molecular docking, drug-likeness, and absorption, distribution, metabolism, and excretion (ADME) protocols. The molecular docking results displayed ten compounds that adapted a similar binding mode and orientation within the active site of the VEGFR2 receptor. The molecular dynamic (MD) simulation analysis of the best hit, 3C, was carried out to validate the docking data. The RMSD and RMSF analysis was used to explain the stability of the VEGFR2 and 3c during the 50 ns simulation trajectory. The MD output revealed that the complex maintained conformational stability and consistent flexibility throughout the run. The results of the docking and simulation techniques supported each other. Thus, 3c emerged as a promising oxa/thiazole carboxamide-carrying lead molecule in our search for potential triple-negative breast cancer therapy.
Citation Format: Steven M. Ewell, Getinet Mequanint, Donald Sikazwe, Kinfe Redda, Bereket Mochona. In-silico identification of oxa/thiazole carboxamides as potential breast cancer therapeutic agents with vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitory effect [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B005.
Abstract B023: Monoclonal gammopathy of undetermined significance and multiple myeloma survival among Hispanics living in Puerto Rico
Authors: Castañeda-Avila Maira , Suárez-Ramos Tonatiuh , Torres-Cintrón Carlos R. , Gierbolini-Bermúdez Axel , Ortiz-Ortiz Karen J. 
Published: December 2023

Abstract
Background: Monoclonal Gammopathy of Undetermined Significance (MGUS) is a pre-malignant condition that may progress to multiple myeloma (MM). The aim of this study was to investigate the effect of previous MGUS diagnosis on MM survival. Methods: Data from the Puerto Rico Central Cancer Registry-Health Insurance Linkage Database were analyzed. The study included incident cases of MM diagnosed between 2010 and 2016. Patients with a previous MGUS diagnosis were identified through a claims-based algorithm. Competing-risk modeling was used to estimate the impact of previous MGUS on MM survival, adjusting for sex, age, comorbidity index, and insurance. The results were stratified by sociodemographic characteristics. Results: Of the 1,205 patients diagnosed with MM, 9.7% (n=117) had a previous diagnosis of MGUS. Patients with a previous MGUS diagnosis were found to be older, with a higher comorbidity index, and had Medicare compared to those without a previous MGUS diagnosis. Additionally, these patients were less likely to die from MM (SHR: 0.48, 95%CI=0.33-0.71) than those without a previous MGUS diagnosis. The magnitude of the association between MGUS and MM mortality varied by sociodemographic characteristics. For example, patients between 40-69 years with a previous MGUS diagnosis were less likely to die from MM (SHR:0.23, 95%CI=0.09-0.60) than those without MGUS. Patients with MGUS and ≤1 comorbidity index were also less likely to die from MM (SHR:0.31, 95%CI=0.18-0.55) than those without MGUS with the same comorbidity index. Males with MGUS were less likely to die from MM (SHR:0.41, 95%CI=0.22-0.73), but the association was weaker among females. Patients with MGUS and Medicare were less likely to die from MM (SHR:0.43, 95%CI=0.25-0.74) than those without MGUS who also had Medicare. No significant association was found between MGUS and MM mortality among patients with other insurance types, other age groups, and other comorbidities index. Conclusion: Findings show that males, younger adults, and those with low comorbidity may benefit from a prior MGUS diagnosis, indicating that patients with a previous MGUS diagnosis may have improved survival due to earlier access to more effective treatments for MM. Further research is necessary to gain a comprehensive understanding of the underlying mechanisms.
Citation Format: Maira Castañeda-Avila, Tonatiuh Suárez-Ramos, Carlos R. Torres-Cintrón, Axel Gierbolini-Bermúdez, Karen J. Ortiz-Ortiz. Monoclonal gammopathy of undetermined significance and multiple myeloma survival among Hispanics living in Puerto Rico [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B023.
Abstract B027: Evaluation of dnaja2:A target for chemotherapy sensitization of cancer cells
Authors: Bai Feng , Rozas Hernan Flores 
Published: December 2023

Abstract
Breast cancer is the second most common cause of death from cancer in women in the United States. The disease accounts for 1 in 3 of new female cancers annually. Triple-negative breast cancer (TNBC) is the most aggressive and fatal subtype of breast cancer. TNBC is estrogen receptor-negative, progesterone receptor-negative, and HER2-negative providing fewer treatment options and resulting in worse prognosis. There are a variety of chemotherapy drugs used to treat TNBC but they may cause serious side effects which limit their use. Our laboratory has investigated the pathways that protect cells from anthracyclines, a commonly used chemotherapy agent. Through a genetic screening in the yeast S. cerevisiae, we identified YDJ1, which encodes for a gene involved in the heat-shock response pathway, that when inactivated rendered cells over 100-fold more sensitive to doxorubicin. YDJ1 is a homolog of the human gene DNAJA2 (DnaJ homolog subfamily A member 2). The protein encoded by this gene belongs to the DNAJ/HSP40 family of proteins, which regulate molecular chaperone activity by stimulating ATPase activity of Hsp70 promoting the folding of denatured proteins. We hypothesize that DNAJA2 protects cells from anthracycline exposure. To evaluate the role of DNAJA2 in the sensitivity of cancer cells exposed to doxorubicin, we knocked down DNAJA2 in the TNBC cell line MDA-MB-231 using a lentivirus-based shRNA. Cells were made stably transfected by continued selection with puromycin. Resulting knockdown cells show significant reduction of DNAJA2 protein. In addition, the cells also show accumulation of ROS, decreased cell mobility and decreased resistance to anticancer agents such as doxorubicin. Additional phenotypes are currently under investigation, as well as the interaction of the other members of the DNAJA family of proteins. We hope that our data contributes to the development of protocols to sensitize cancer cells to chemotherapy. Funding provided by the Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center. Tissue Modeling Core. U54CA233396, subproject 6636
Citation Format: Feng Bai, Hernan Flores Rozas. Evaluation of dnaja2:A target for chemotherapy sensitization of cancer cells [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B027.